Compare FOA & VYGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FOA | VYGR |
|---|---|---|
| Founded | 2013 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 221.6M | 203.6M |
| IPO Year | 2021 | 2015 |
| Metric | FOA | VYGR |
|---|---|---|
| Price | $22.26 | $3.23 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $26.00 | $16.50 |
| AVG Volume (30 Days) | 48.1K | ★ 546.3K |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 216.95 | N/A |
| EPS | ★ 0.41 | N/A |
| Revenue | ★ $497,432,000.00 | $10,135,000.00 |
| Revenue This Year | $0.58 | $34.04 |
| Revenue Next Year | $6.91 | $7.92 |
| P/E Ratio | $53.66 | ★ N/A |
| Revenue Growth | ★ 47.09 | N/A |
| 52 Week Low | $15.77 | $2.94 |
| 52 Week High | $29.79 | $5.55 |
| Indicator | FOA | VYGR |
|---|---|---|
| Relative Strength Index (RSI) | 46.01 | 50.65 |
| Support Level | $22.10 | $2.95 |
| Resistance Level | $24.03 | $3.28 |
| Average True Range (ATR) | 1.18 | 0.15 |
| MACD | -0.19 | 0.04 |
| Stochastic Oscillator | 27.38 | 75.95 |
Finance of America Companies Inc provides home equity-based financing solutions for modern retirement and offers capital markets and portfolio management capabilities to optimize loan distribution to investors. The Company operates through two segments: Retirement Solutions and Portfolio Management. The Retirement Solutions segment handles loan origination, including HECM and non-agency reverse mortgage loans, generating revenue from origination fees and initial gains, with loans transferred to the Portfolio Management segment. The Portfolio Management segment, which generates the majority of revenue, provides securitization, loan sales, risk management, and asset management services, and earns revenue from net interest income, fair value changes, and servicing-related income.
Voyager Therapeutics Inc is a biotechnology company to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; Parkinson's disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of its programs are derived from its TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which the company has used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous, or IV, dosing. Its segment is developing and commercializing genetic medicine.